docetaxel

On The Horizon- FDA Grants Fast Track Designation for OGX-011 in The Treatment of Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]

By Malecare|2017-10-19T10:54:28-04:00October 12th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Metastases, On The Horizon, Uncategorized|0 Comments

Carboplatin-Taxane Combinations in the Management of Castration-resistant Prostate Cancer

The use of Docetaxel (chemotherapy) extends survival time in men with castration-resistant prostate cancer (CRPC). Many researchers believe that platinum compounds, particularly Carboplatin, when added to docetaxel (taxane-based chemotherapy) can further extend survival times. A study at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Investigated the efficacy [...]

By Malecare|2020-02-04T11:38:11-05:00September 3rd, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments

Mitoxantrone Plus Prednisone – A Possible Fallback After Taxotere Failure

Men with metastatic hormone-refractory prostate cancer (mHRPC) who become docetaxel-refractory (no longer responsive to docetaxel therapy have no approved second line chemotherapy available. One could say that they have reached the proverbial brick wall. Where to go and what to do is not at all clear. Most of us do not want to just roll [...]

By Malecare|2017-10-19T10:54:46-04:00July 20th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, End-Of-Life, How We Live, Uncategorized, Understanding APC|0 Comments

Increased Levels of C-Reactive Protein is Confirmed to Limit Survival

A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]

By Malecare|2009-06-22T09:53:05-04:00June 22nd, 2009|Advanced Prostate Cancer, General Information, Research, Uncategorized, Understanding APC|0 Comments

Toxicity and Efficacy of Intermittent Docetaxel Chemotherapy for Hormone Refractory Prostate Cancer

Once we become hormone refractory (HRPC) there remains only one approved drug to treat our prostate cancer, docetaxel. As with hormone therapy (ADT) docetaxel also stops working after a period. There have been different strategies used to try to deal with this untenable situation, including the use of docetaxel on an intermittent schedule. A recent [...]

By Malecare|2017-10-19T10:55:15-04:00May 28th, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments

Can Bone Pain Predict Survival in Men with Metastatic Hormone-Refractory Prostate Cancer Treated with Docetaxel? What are the Implications?

A small study of 145 men with asymptomatic metastatic hormone-refractory prostate cancer (HRPC) was conducted to determine the benefit of starting early chemotherapy with docetaxel. Collected data were analyzed from these subjects who were treated with chemotherapy between February 2000 and June 2002 in one French center. The men were categorized into three groups according [...]

By Malecare|2009-03-16T08:11:28-04:00March 16th, 2009|Advanced Prostate Cancer, Drugs & Treatments, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer Is Viable

There have been very few studies on the patterns of care and outcome of elderly (over 75 years) survivors with androgen independent prostate cancer (AIPC) who have been treated with docetaxel (Taxotere). The records of 175 French men with AIPC, over the age of 75 years, were retrospectively examined. All of the men were treated [...]

By Malecare|2017-10-19T10:57:01-04:00September 19th, 2008|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Uncategorized|1 Comment